Professor of Thoracic Radiation Oncology, University of Manchester and Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust.

Corinne Faivre-Finn, FRCR, MD, PhD, is a Professor of Thoracic Radiation Oncology at the Division of Molecular and Cancer Sciences (University of Manchester) and Honorary Consultant Clinical Oncologist (The Christie NHS Foundation Trust, Manchester) with a specialist interest in lung cancer. Prof Faivre-Finn trained in Paris until 1998 and accepted a consultant post at The Christie in 2001. Her interests lie in the development of adanced radiotherapy techniques and combined modality treatments for stage III non small-cell lung cancer and limited disease small-cell lung cancer.

Prof Corinne Faivre-Finn has been an active clinical researcher in the field of lung cancer for over 13 years, developing research expertise in the field of combined modality treatment in lung cancer.

 Prof Faivre-Finn has been successful in securing several research grants, including CR-UK and NIHR funding.  She is involved with the protocol development of several national and international clinical trials in lung cancer. She is Chief investigator (CI) of the international CONVERT study (limited-disease SCLC), PIT study (Mesothelioma), Isotoxic IMRT (NSCLC) and MEKRT (MEK inhibitor combined with thoracic radiotherapy in NSCLC) and the UK chief investigator for the LungTech and LungART studies.

Prof Corinne Faivre-Finn is also involved with the trial management groups of several UK lung cancer clinical trials and has been acting as site Principal Investigator for major national and international trials; demonstrating the capability to recruit large numbers of patients while providing good quality data.

• Supervision for 4th year option project for University of Manchester Medical Students
• Formal teaching for Specialist Registrars on the lung team and FRCR part 2 teaching
• Supervision of MRes students (first essay prizes awarded to 2 supervised students by the RCR and the Manchester Oncology Society)
• Supervision of MD and PhD fellows
• Advisor to PhD students
• External MD/PhD reviewer
• External MD examiner
• ESMO masterclasses

• Christie Medical Oncology (Paul Lorigan and Fiona Blackhall), Joint projects including clinical trials (CONVERT, MEKRT see above) and translational research projects (RADAR).
• Cancer Research UK Manchester Institute (Caroline Dive, Fiona Blackhall, Catharine West). Collaboration on the RADAR study. This is a prospective study in which patients with SCLC or NSCLC who are treated with radical RT, with or without chemotherapy are asked to donate tumour tissue and blood samples for research. The results from the tissue and blood samples combined with clinical data, will be used to discover and evaluate novel biomarkers present in blood and tissue with clinical utility to predict for RT response, resistance and/or toxicity. In time this study should feed in to the wider theragnostics project.
• Wolfson Molecular Imaging Centre (Alan Jackson, Marie Claude Asselin). Collaboration on the RADAR study. A proportion of patients with NSCLC in RADAR are undergoing functional imaging scans (FLT PET, or advanced MRI techniques), in addition to providing tissue and blood samples, to evaluate physiological and molecular changes within tumour and normal tissue during RT. The aim of the functional imaging sub-study in RADAR is to characterise imaging biomarkers relevant to clinical trials incorporating RT with or without drugs.
• School of Pharmacy and Pharmaceutical Sciences (Kaye Williams and Ian Stratford). Their preclinical research led to the initiation of the MEKRT trial (see above).
• Christie Medical Physics and Engineering (Ran Makay, Carl Rowbottom, Chris Moore) and Wade Centre (Julie Stratford). Collaboration on the development of advanced radiotherapy techniques which has led to the funding of the isotoxic IMRT study by CRUK.
• External Collaborators: Prof. Dirk de Ruysscher (Maastricht), Dr Cecile le Pechoux (Institute Gustave Roussy, Paris), Prof. Ursule Nestle (Freiburg)
• Numerous EORTC and Radiotherapy groups.

She is involved in several national and international research committees including:

• Early disease Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Group,  2015 – date
• Radiotherapy Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Group,  2008 – 2014
• Radiotherapy Research lead of the CRUK lung cancer centre of excellence, 2014 - date
• Lung Disease Site Coordinator of the Elekta and Philips MR linac Research Consortium
• Manchester Cancer Research Centre (MCRC) radiotherapy research lead, 2012 – date
• Member of the Advanced Radiation Technology (ART) Committee – International Association for the Study of Lung Cancer (IASLC), 2012-date
• Member of the ESMO Lung Cancer Consensus Conference, 2013-2014
• Member of the European Respiratory Society ‘European Initiative for Quality Management in Lung Cancer Care task force’, 2010-2013
• Member of the European Respiratory Society ‘Fitness for radical therapy in lung cancer task force’, 2008 – 2009
• Member of the NCRN limited stage small cell lung cancer and stage I-III non-small-cell lung cancer subgroup (LORD subgroup), 2005-date

• Member of Workstream 3 (phase III clinical trials) of the NCRI Clinical & Translational Radiotherapy Research Working Group (CTRad), 2009-date

• Member of the British Thoracic Oncology Group Steering Committee, 2010-date

• Member of the British Thoracic Society Guidelines Committee on Mesothelioma, 2014-2016

• Radiotherapy research lead for the CRUK lung cancer centre of excellence, 2014-date

• CRUK Clinical Expert Review Panel, 2015-date

• Clinical trials
• External MD/PhD reviewer
• External MD examiner
• ESMO masterclasses

FRCR

MD

PhD

CRUK fundraising